Tsakos Energy Navigation Limited (NYSE:TEN) Q4 2024 Earnings Conference Call March 27, 2025 11:00 AM ET Company Participants Nicolas Bornozis - Investor Relations, Capital Link Takis Arapoglou - Chairman of the Board Nikolas Tsakos - Founder & Chief Executive Officer George Saroglou - President & Chief Operating Officer Harrys Kosmatos - Co-Chief Financial Officer Conference Call Participants Poe Fratt - Alliance Global Partners Climent Molins - Value Investor's Edge Operator Good morning to all. Thank you ...

INmune Bio, Inc. (NASDAQ:INMB) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Global Partners Operator Greetings, and welcome to the INmune Bio’s. 2024 Fourth Quarter and Full Year Earnings Call. ...

BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Stephen Kilmer ??? Investor Relations Lance Alstodt ??? Chairman and Chief Executive Officer Rob Kristal ??? Chief Financial Officer Francisco Silva ??? Vice President-Research and Development Conference Call Participants Michael Okunewitch ??? Maxim Group Elemer Piros ??? Rodman & Renshaw Operator Good afternoon, everyone, and welcome to the BioRestorative Therapies 2024 Results Conf ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Uy Ear - Mizuho Securities Andrew Tsai - Jefferies Operator Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal present ...

Financial Data and Key Metrics Changes - Preliminary revenues for Q4 2024 increased between 17.9% and 20.7% year-on-year, marking the third consecutive year of nearly 20% revenue growth [35][37] - Gross margins for Q4 were expected to be between 46% and 48.5%, up 200 basis points from Q4 2023, with annual gross margins over 46% [28][36] - Fiscal year revenues for 2024 are projected to be between $48.9 million and $49.2 million, compared to $41.168 million in 2023, representing an annual growth rate of 18.8% to 19.5% [37][38] Business Line Data and Key Metrics Changes - The aerospace and defense sector accounted for approximately 70% of the company's business, with 85% of that being program-driven contracts [41] - The company announced two significant contract wins, each exceeding $10 million, which are expected to strengthen the sales pipeline [20][21] Market Data and Key Metrics Changes - Despite potential defense budget cuts discussed in Washington, customer engagement and sales processes remain strong, with expectations for continued robust bookings and revenue [23][24] - European defense spending is anticipated to increase, with over 60% of European defense procurement budgets allocated to U.S. defense suppliers [25] Company Strategy and Development Direction - The company plans to explore partnerships and acquisitions for inorganic growth, aiming to expand its product portfolio and customer base [30][32] - A focus on maintaining strong margins and cash accumulation is evident, with gross margins expected to remain in the high 40s [28][43] - The company is also investing in a Connectivity Partnership to explore new market opportunities in RF communications [30][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to exceed the previously guided growth rate of 10%, citing strong performance in Q1 2025 [79] - The management team is focused on maintaining high gross margins and leveraging existing strengths to drive future growth [28][43] Other Important Information - The company announced a shift from a rights offering to a warrant dividend to distribute value to shareholders, allowing for a longer-term right to purchase shares [57][61] - The warrant dividend will allow shareholders to purchase one common share for every five warrants held, with a strike price of $47.50 [60] Q&A Session Summary Question: Is there something imminent for M&A? - Management indicated that while there is no imminent deal, there are many opportunities in the M&A market [66] Question: Are the large contract wins with the same customers? - The recent contract wins were with two different large customers, and there are more contracts expected in the pipeline [70] Question: How will the Connectivity Partnership work? - The Connectivity Partnership will provide insights into broader market opportunities and may lead to potential acquisitions or partnerships [75] Question: What is the expected revenue growth in the coming years? - Management guided for a conservative growth expectation of around 10%, with potential to exceed that based on current performance [79] Question: How are gross margins expected to trend? - Management expects gross margins to remain in the high 40s, with some fluctuations quarter-to-quarter [83] Question: What metrics are used to evaluate accretive acquisitions? - The focus is on EBITDA-to-EBITDA comparisons, with a preference for immediate accretive deals [99] Question: What are the incentives for management? - Senior management is incentivized through cash-based performance bonuses and equity participation through restricted stock [102]

Faraday Future Intelligent Electric Inc. (FFIE) Q4 2024 Earnings Conference Call March 27, 2025 08:00 PM ET Company Participants Operator - Conference OperatorBrad Cohen - External Investor Relations ModeratorJun Sun - Head of Investor RelationsMatthias Eid - Global CEOMax Ma - Global CEO of FaradayXCody Mecca - CFOAnshul Rai - Tech Lead, Intelligence, Autonomous Driving and Internet DepartmentJerry Wang - President Operator Greetings. Welcome to Faraday Future Intelligent Electric, Inc. Fourth Quarter 2024 ...

FitLife Brands, Inc. (NASDAQ:FTLF) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants Dayton Judd - Chief Executive Officer Jakob York - Chief Financial Officer Conference Call Participants Ryan Meyers - Lake Street Capital Markets Samir Patel - Askeladden Capital James Bogan - Legend Capital Igor Novgorodtsev - Lares Capital Sean McGowan - ROTH Capital Partners Operator Good day, and welcome to the FitLife Brands' Fourth Quarter 2024 Financial Results. At this time, all particip ...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Welcome to Plus Therapeutics' Fourth Quarter and Full Year 2024 Results Conference Call. Before we begin, we want to advise you that over the course of the call, including any question-and-answer session, for ...

Financial Data and Key Metrics Changes - The company reported consolidated net sales for fiscal 2024 decreased by 3% to $1.52 billion, with a notable impact from a 53rd week in 2023 contributing approximately $16 million in sales [26] - Adjusted EPS for the fourth quarter was $6.68, at the top end of guidance [33] - Adjusted gross margin contracted by 80 basis points to 63.2%, primarily due to a higher proportion of sales occurring during promotional events [28] Business Line Data and Key Metrics Changes - Sales in full-price brick-and-mortar locations decreased by 2%, driven by mid-single-digit negative comps, partially offset by new store openings [26] - E-commerce sales decreased by 4%, while food and beverage and outlet locations saw sales increases of 1% and 3%, respectively [27] - The wholesale channel experienced a significant decline, decreasing by $31 million or 10% due to challenges in the specialty store business [27] Market Data and Key Metrics Changes - Comp sales for December increased by 2%, but January saw a decline of 3%, with February experiencing a further drop of 9% [7][9] - The company anticipates a continued cautious consumer sentiment impacting spending in the near term [11] Company Strategy and Development Direction - The company focuses on maximizing long-term shareholder value, owning a portfolio of lifestyle brands, evoking happiness in consumers, and generating cash for reinvestment [12][13][15][16] - Plans for fiscal 2025 include opening approximately 20 new stores and enhancing the omnichannel platform [22][39] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the uncertainty in the marketplace and expects consumer hesitance to continue, particularly in the first half of fiscal 2025 [11] - The company remains optimistic about long-term opportunities despite short-term challenges, emphasizing the importance of brand integrity and customer focus [14][16] Other Important Information - The company plans to invest approximately $125 million in capital expenditures for fiscal 2025, primarily for the completion of a new distribution center and new store openings [44] - A 3% increase in the quarterly dividend was approved, raising it from $0.67 to $0.69 [23] Q&A Session Summary Question: Can you unpack the different headwinds mentioned for the first quarter? - Management noted that Lilly is currently the strongest performer, while Tommy Bahama and Johnny Was are expected to have negative comps [52][53] Question: Are you observing any changes in wholesale order books? - Management indicated that there is caution among wholesale partners, but performance on retail floors remains strong [56][94] Question: What initiatives are being taken to improve conversion rates? - The company is focusing on better product knowledge among associates, improving website functionality, and enhancing marketing efficiency [73] Question: What is the outlook for March sales? - Management expressed that March feels better than February, with expectations for a positive comp in April due to the Easter shift [81] Question: How is the company managing SG&A growth? - Management is actively looking at marketing efficiency, vendor negotiations, and has made some personnel reductions to control SG&A [87]

Financial Data and Key Metrics Changes - Research and development revenue for Q4 2024 was $7.6 million, up from $5.3 million in the prior year, reflecting increased work under the BARDA PBS contract [28] - Full year 2024 R&D revenue reached $29.6 million, a 63.5% increase from $18.1 million in 2023, marking the highest revenue in the company's history [30] - Gross margin for Q4 2024 declined to 44% from 46.1% in the prior year, while full year gross margin rose to 44.9% from 43.6% [30][31] - General and administrative expenses decreased to $4.6 million in Q4 2024 from $5.4 million in the prior year, and full year expenses were $19.9 million compared to $20.9 million in 2023 [30][32] - Cash and cash equivalents totaled $5.2 million as of December 31, 2024, with a current cash position exceeding $14 million following long-term debt financing [33] Business Line Data and Key Metrics Changes - The DeepView system demonstrated exceptional performance in a burn validation study, significantly outperforming clinical judgment in sensitivity, Dice score, and specificity [12][14] - The DeepView system's sensitivity was 86.6%, compared to 40.8% for clinicians, while the Dice score was 68.5% versus 39.2% for burn physicians [13][14] Market Data and Key Metrics Changes - The company has successfully deployed three DeepView systems in Australia at leading hospitals, enhancing its presence in the U.K. and Australia [20] - The response from burn specialists in the U.K. and Australia has been exceptionally positive, indicating strong enthusiasm for the technology [17] Company Strategy and Development Direction - The company aims to submit results to the FDA by the end of Q2 2025, seeking De Novo classification in 2026 [15] - A dedicated intellectual property subsidiary, Spectral IP, was formed to monetize IP assets, with plans to spin off into an independent publicly traded company [24][26] - The company is focused on improving operational efficiencies and concentrating on the DeepView system as part of the BARDA PBS contract [34] Management's Comments on Operating Environment and Future Outlook - Management anticipates a slight revenue decline in 2025 as the company prepares for FDA submission, with expectations for a ramp-up in 2026 [58] - The company has a sound financial foundation to pursue strategic objectives and bring the DeepView system to commercialization [35] Other Important Information - The development of the SnapShot M, a portable diagnostic tool, is supported by over $7 million in government funding, with military deployment anticipated in 2027 [23] - The company is gathering real-world clinical data to strengthen its case for FDA submission and support global commercialization strategies [16] Q&A Session Summary Question: Plans for commercialization and staffing - Management plans to precondition the market with studies and mobilize a sales force as they anticipate FDA clearance [42][43] Question: Revenue guidance for 2025 - Management expects a step back in revenue for 2025 as they position for FDA submission, with a focus on additional developments for quick commercialization post-clearance [58] Question: FDA submission requirements - The submission will include a comprehensive package with multiple sections, reviewed by BARDA before submission to the FDA [60][61] Question: Additional deployments in Australia and the U.K. - No additional units are planned for deployment; focus will be on training and gathering feedback from existing sites [72] Question: Timeline for pediatric study data - The pediatric study data is merged with adult data, and preliminary processing has been completed [84][86] Question: Development milestones for SnapShot M - Preliminary feedback from military testing is being incorporated, with completion expected in 2025 [88] Question: Learnings from U.K. deployments - Positive feedback has been received, and the company anticipates sharing data at upcoming scientific meetings [92][93]